Live Breaking News & Updates on Paediatric Committee

Stay updated with breaking news from Paediatric committee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 . ....

Elizabeth Coleman , John Menditto , Corporate Communications , Lisata Therapeutics Inc , European Medicines Agency , European Union , Exchange Commission , Paediatric Committee , Paediatric Investigation Plan , Executive Vice President , Chief Medical Officer , Paediatric Regulation , Fast Track , Orphan Drug Designation , Rare Pediatric Disease Designation , Private Securities Litigation Reform Act , Nasdaq Capital Market , Annual Report , Investor Relations ,

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines ...

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed ....

Elizabeth Coleman , John Menditto , European Medicines Agency , Paediatric Committee , Lisata Therapeutics Inc , European Union , Exchange Commission , Corporate Communications , Paediatric Investigation Plan , Executive Vice President , Chief Medical Officer , Paediatric Regulation , Fast Track , Orphan Drug Designation , Rare Pediatric Disease Designation , Cendr Platform , Private Securities Litigation Reform Act , Nasdaq Capital Market , Annual Report , Investor Relations ,

Lisata Therapeutics receives waiver for pediatric studies of certepetide in pancreatic cancer

Lisata Therapeutics Inc (NASDAQ:LSTA) has received a Paediatric Investigation Plan (PIP) waiver from the European Medicines Agency (EMA) for its lead. ....

Lisata Therapeutics Inc , European Medicines Agency , Paediatric Committee , Paediatric Investigation Plan ,

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

CEL-SCI Corporation today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments.

Clinical and Corporate Developments. ....

United States , Geert Kersten , Securities Exchange , European Union , Drug Administration , Exchange Commission , European Medicines Agency Paediatric Committee , Corporate Developments , Registration Study , European Medicines Agency , Paediatric Committee , Leukocyte Interleukin , Orphan Drug , Securities Act , Securities Exchange Act ,

Cessatech: Cessatech announces positive topline data from study 0205 with its lead candidate CT001 for the treatment of pain in children supporting further advancement of CT001 -December 22, 2023 at 07:35 am EST

Press release from Companies

Publicerat: 2023-12-22 13:33:27

Cessatech A/S: Cessatech announces positive topline data from study 0205 with its lead candidate. ....

Cessatechas Cessatech , Jes Trygved , Paediatric Committee , Investigation Plan , Paediatric Investigation Plan , Principal Investigator ,